Multiple System Atrophy (MSA)

Bulbar-focussed digital endpoints

Purpose-built tools for capturing dysarthria and dysphagia, which are early and prominent features in MSA.

Sensitive to MSA subtypes

Algorithms tailored for parkinsonian (MSA-P) and cerebellar (MSA-C) presentations, capturing speech variability and motor control.

Regulatory-aligned speech biomarkers

Objective, repeatable measures to support longitudinal tracking and therapeutic efficacy for MSA.

Validated across rare disease cohorts

Proven implementation in low-prevalence neurodegenerative populations with remote, scalable deployment.

Real-world function and quality of life insight

Speech and swallowing outcomes aligned with patient-centred metrics such as intelligibility, communication burden and nutritional risk.

Speech, language, and swallowing decline in (MSA) are directly linked to disease severity and patient function, serving as sensitive markers of progression. Redenlab’s digital assessments offer quantifiable, low-burden endpoints for tracking bulbar and cognitive-motor changes in clinical trials.

Why speech matters in Multiple System Atrophy

MSA is a rare, rapidly progressive neurodegenerative disorder with hallmark features of dysarthria and dysphagia affecting over 90% of individuals as the disease advances. These impairments significantly impact communication, nutritional safety, and independence, contributing to social withdrawal and reduced quality of life. The progression of speech and swallowing symptoms can be difficult to track with traditional assessments. Redenlab provides objective, high-frequency digital monitoring tools that capture subtle changes in bulbar and cognitive-motor function to support clinical decision-making and treatment evaluation.